Maxim starts VSee Health at Buy, sees good momentum in new contracts

As previously reported, Maxim analyst Allen Klee initiated coverage of VSee Health (VSEE) with a Buy rating and $5 price target The company offers a low-code / no-code telehealth solution that is wrapped with AI and provides specialty intensive care unit offerings, the analyst tells investors in a research note. VSee also has a customer base with major organizations, and offers competitive advantages vs. alternatives, Maxim adds, stating that with good momentum in signing new contracts, it sees revenue of $10.1M in 2024.